DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with a poor prognosis that is characterized by excessive mitogenic pathway activation and marked chemoresistance to a broad spectrum of chemotherapeutic drugs. Dual specificity protein phosphatase 1 (DUSP1) is a key negative regulator of mit...
Guardado en:
Autores principales: | Fang Liu, A Jesse Gore, Julie L Wilson, Murray Korc |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2f551db8aca741ffb4bf3fe21fc5c62e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
por: Ru Chen, et al.
Publicado: (2017) -
Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo ZY, et al.
Publicado: (2018) -
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong DJ, et al.
Publicado: (2013) -
OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
por: Jinsheng Ding, et al.
Publicado: (2021) -
Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabine
por: Mina Emamzadeh, et al.
Publicado: (2021)